NCT00889135Approved For Marketing不适用
Long Term Treatment With L-DOPS
适应症
试验速览
- 阶段
- 不适用
- 状态
- Approved For Marketing
- 试验地点
- 1
研究概览
简要总结
This study is designed to supply L-DOPS (droxidopa) on a long term basis to patients with a genetic form of profound orthostatic hypotension, most commonly DBH deficiency. It also allows us to collect medical history information on this small population of patients that would allow us to determine if there are any complications from this type of treatment.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 years old or older with orthostatic hypotension
- •established diagnosis of DBH deficiency and fractionated plasma catecholamine levels that show high dopamine levels and very low norepinephrine and epinephrine levels. Blood pressure increase in response to oral treatment with L-DOPS during previous studies.
排除标准
- •subjects with orthostatic hypotension that do not have a genetic form of the disorder and catecholamine pattern is not consistent with that above.
研究者
David Robertson
Professor of Medicine and Pharmacology
Vanderbilt University
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)Neurogenic Orthostatic HypotensionNon-Diabetic Autonomic NeuropathyDopamine Beta Hydroxylase DeficiencyMultiple System AtrophyNCT00738062Chelsea Therapeutics103
已完成
1 期
A Dose Titration of Droxidopa in Patients With Spinal Cord InjurySpinal Cord InjuryHypotensionNCT01354158Bronx VA Medical Center11
已完成
3 期
RESCUE and REVERSE Long-term Follow-upLeber Hereditary Optic NeuropathyNCT03406104GenSight Biologics62
终止
4 期
Maintenance Phase Treatment With Divalproex for Post Traumatic Stress DisorderPTSDNCT00203385Tuscaloosa Research & Education Advancement Corporation20
终止
3 期
Phase III Long-Term Extension Study With DexpramipexoleEosinophilic AsthmaNCT06388889Areteia Therapeutics509